Gelonghui, January 22丨An investor asked Saisheng Pharmaceutical (300485.SZ) on the investor interactive platform, “Does the company's strong kidney granules account for 1% of the company's operating revenue in the market?” The company replied that Qiangkidney Granule is a product of its subsidiary Junyuan Pharmaceutical. The product has completed a change in production site and can be marketed for sale. Sales work is gradually being carried out, and currently it does not account for much of the company's overall revenue.
赛升药业(300485.SZ)：强肾颗粒为子公司君元药业的产品，目前在公司整体营业收入中占比不大
Saisheng Pharmaceutical (300485.SZ): Strong Kidney Granules are a product of the subsidiary Junyuan Pharmaceutical. Currently, they do not account for much of the company's overall revenue
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.